Lavipharm (LAVI) Q1 2025 earnings summary

Executive summary

• EBITDA rose 32.4% year-over-year to €3.77 million, driven by both continuing and discontinued operations.

• Net profit after tax increased 46.8% to €1.63 million compared to Q1 2024.

• Domestic prescription drug sales surged 40%, while exports declined 27.8% due to temporary order delays.

Financial highlights

• Consolidated sales before rebates and clawbacks grew 2.7% to €14.71 million year-over-year.

• Net sales increased 1.8% to €12.70 million; gross profit up 1.3% to €6.03 million.

• Adjusted EBITDA from continuing operations rose 6.6% to €2.82 million.

• EBIT from continuing operations slightly decreased by 2.5% to €1.56 million.

• Earnings after tax from continuing operations fell 27.5% to €0.69 million.

Outlook and guidance

• Export sales decline is expected to be temporary, with order execution delays anticipated to be resolved during the year.